There are no official guidelines to assist in answering this question. I will search for relevant research papers instead.
The FDA Drug Labels for budesonide (INH), glycopyrronium (INH), formoterol (INH) do not address this question.
From the Research
Breztri (Budesonide, Glycopyrrolate, Formoterol) Usage
- Breztri is used for the maintenance treatment of chronic obstructive pulmonary disease (COPD) 1, 2, 3, 4, 5
- It is a triple therapy that combines an inhaled corticosteroid (budesonide), a long-acting muscarinic antagonist (glycopyrronium), and a long-acting β2-agonist (formoterol) 2
- The treatment has been shown to reduce the risk of moderate to severe COPD exacerbations, improve lung function, and enhance health-related quality of life compared to dual therapies 1, 2, 3, 4, 5
Benefits of Breztri
- Reduces the risk of moderate to severe COPD exacerbations 1, 2, 3, 4, 5
- Improves lung function, as measured by forced expiratory volume in 1 second (FEV1) 1, 2, 3
- Enhances health-related quality of life, as assessed by the St George's Respiratory Questionnaire and the Transition Dyspnea Index 2, 4, 5
- Reduces the need for rescue medication 4, 5
- May reduce the risk of all-cause mortality 2
Patient Populations
- Breztri has been studied in patients with moderate to very severe COPD, including those with a history of exacerbations 1, 2, 3, 4, 5
- The treatment has been shown to be effective in patients with and without prior use of inhaled corticosteroids 4
- Benefits of Breztri have been observed across different blood eosinophil count ranges, including those with counts ≥100 cells/mm³ 5